Citizens Jmp Forecasts Strong Price Appreciation for Omada Health (NASDAQ:OMDA) Stock

Omada Health (NASDAQ:OMDA) had its price target upped by Citizens Jmp from $18.00 to $21.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s target price points to a potential upside of 34.21% from the stock’s previous close.

Several other brokerages have also recently commented on OMDA. Morgan Stanley lowered their price target on Omada Health from $32.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, March 6th. Citigroup reiterated an “outperform” rating on shares of Omada Health in a research note on Friday. BMO Capital Markets decreased their target price on shares of Omada Health from $27.00 to $18.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Barclays lowered their target price on shares of Omada Health from $22.00 to $17.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Finally, Wall Street Zen upgraded Omada Health from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.64.

Omada Health Price Performance

OMDA traded down $0.75 during trading on Friday, reaching $15.65. 604,677 shares of the stock traded hands, compared to its average volume of 1,210,898. The stock’s 50-day simple moving average is $13.55 and its two-hundred day simple moving average is $15.85. Omada Health has a fifty-two week low of $10.28 and a fifty-two week high of $28.40. The stock has a market cap of $929.74 million and a price-to-earnings ratio of -91.83.

Omada Health (NASDAQ:OMDA) last issued its earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.03. The firm had revenue of $78.05 million during the quarter. Research analysts anticipate that Omada Health will post -0.04 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Steven L. Cook sold 1,884 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $13.94, for a total value of $26,262.96. Following the transaction, the chief financial officer directly owned 200,512 shares in the company, valued at approximately $2,795,137.28. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Sean P. Duffy sold 4,063 shares of the firm’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $14.34, for a total transaction of $58,263.42. Following the completion of the transaction, the chief executive officer owned 117,598 shares in the company, valued at $1,686,355.32. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 8,776 shares of company stock valued at $120,483.

Hedge Funds Weigh In On Omada Health

Several large investors have recently bought and sold shares of the stock. Quarry LP acquired a new stake in Omada Health in the 4th quarter worth $29,000. TD Waterhouse Canada Inc. bought a new position in shares of Omada Health during the 4th quarter worth about $32,000. Raymond James Financial Inc. acquired a new position in shares of Omada Health during the second quarter valued at about $32,000. Strs Ohio bought a new stake in shares of Omada Health in the third quarter valued at about $38,000. Finally, Inlight Wealth Management LLC bought a new stake in shares of Omada Health in the fourth quarter valued at about $45,000.

More Omada Health News

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Needham reaffirmed a Buy rating and kept a $28.00 price target (~71% upside vs. the recent price), which supports stronger upside expectations for OMDA. Needham Reaffirms Buy ($28 PT)
• Positive Sentiment: Wells Fargo raised its price target to $18.00 and maintained an “Equal Weight” rating, implying modest upside and adding analyst support to the stock. Wells Fargo Raises PT to $18
• Positive Sentiment: Q1 results beat consensus: OMDA reported ($0.05) EPS vs. ($0.08) expected and revenue of $78.05M. The upside to EPS and topline gives short‑term confidence that growth is tracking to plan. Q1 Press Release
• Positive Sentiment: Management set FY‑2026 revenue guidance of $322.0M–$330.0M versus consensus ~$319.1M, indicating modestly higher revenue expectations for the year. That guidance beat is likely supporting the stock move. FY2026 Guidance (Press Release)
• Positive Sentiment: Commercial partnership: Omada will serve as an independent program administrator in Eli Lilly’s Employer Connect program to offer its GLP‑1 Care Track — a distribution channel that could drive membership and medication management revenue. Omada Joins Lilly Employer Connect
• Neutral Sentiment: Earnings call transcript and analysis are available for more detail on unit economics, membership trends and margin drivers — useful for investors who want to vet management’s commentary on growth and monetization. Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Third‑party coverage (Zacks, Markets Insider/MSN) provides metric-level comparisons to estimates and quarter context; these summaries may influence sentiment but contain no new company-guided data beyond the release. Zacks Q1 Metrics Review

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.